Ocular Therapeutix Quarterly Cash Flow Statement
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 7.59 +0.66%
Ocular Therapeutix free cash flow
In the quarter ended Jun 30, 2026, Ocular Therapeutix generated -$67.3 million of operating cash flow and spent $3.4 million on capital expenditures. That left free cash flow of -$70.6 million, a free-cash-flow margin of -524.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ocular Therapeutix cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -78.76M | -88.61M | -64.65M | -69.42M | -67.81M | -64.05M | -48.39M | -36.49M | -43.78M | -64.85M | -29.22M | -516.00K |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.85M | 1.28M | 1.25M | 1.07M | 1.03M | 981.00K | 951.00K | 959.00K | 956.00K | 920.00K | 958.00K | 890.00K |
| Stock-Based Compensation | 14.65M | 15.58M | 11.36M | 11.69M | 9.68M | 10.46M | 7.20M | 6.64M | 11.29M | 7.98M | 4.33M | 4.51M |
| Change in Working Capital | -4.82M | 1.05M | -2.04M | 3.82M | 596.00K | 5.67M | 1.16M | -1.07M | 3.27M | -12.90M | -6.28M | 6.11M |
| Operating Cash Flow | -67.27M | -65.99M | -54.25M | -50.73M | -55.24M | -44.67M | -39.43M | -36.56M | -24.80M | -33.89M | -22.45M | -7.73M |
| Capital Expenditures | -3.37M | -4.66M | -2.84M | -5.99M | -1.25M | -1.93M | -202.00K | -89.00K | -742.00K | -255.00K | -459.00K | -259.00K |
| Investing Cash Flow | -3.37M | -4.66M | -2.84M | -5.99M | -1.11M | -1.93M | -202.00K | -89.00K | -742.00K | -255.00K | -459.00K | -259.00K |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Financing Cash Flow | 2.58M | 294.00K | 449.38M | 10.36M | 97.81M | 4.18M | 4.51M | 4.18M | 2.20M | 321.22M | 108.17M | 51.94M |
| Net Change in Cash | -68.06M | -70.36M | 392.29M | -46.36M | 41.45M | -42.42M | -35.12M | -32.47M | -23.35M | 287.08M | 85.26M | 43.94M |
| Free Cash Flow | -70.64M | -70.66M | -57.09M | -56.72M | -56.48M | -46.60M | -39.63M | -36.65M | -25.54M | -34.14M | -22.91M | -7.99M |
This table shows 12 quarterly periods of Ocular Therapeutix's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow OCUL's reporting calendar. What is a cash flow statement?